Economic savings versus health losses: The cost-effectiveness of generic antiretroviral therapy in the United States

BACKGROUND: US HIV treatment guidelines recommend branded once-daily, one-pill efavirenz/emtricitabine/tenofovir as preferred first-line antiretroviral treatment (ART). With the anticipated approval of generic efavirenz in 2012 in the US, the cost of a once-daily, three-pill alternative (generic efa...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Walensky, Rochelle P., Sax, Paul E., Nakamura, Yoriko M., Weinstein, Milton C., Pei, Pamela P., Freedberg, Kenneth A., Paltiel, A. David, Schackman, Bruce R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2013
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3664029/
https://ncbi.nlm.nih.gov/pubmed/23318310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7326/0003-4819-158-2-201301150-00002
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak